Insulet Stock: Strong Buy Despite Downturn?

Insulet Corporation, a global medical device company, is facing a challenging period with its stock experiencing a notable decline. Year-to-date, Insulet's shares have fallen by 48.7%, significantly underperforming the broader health care sector. This performance contrasts with the company's recent announcement of raising its full-year 2026 revenue growth guidance, now projected to be between 21% and 23%.

The company's flagship products include the Omnipod 5 Automated Insulin Delivery system, with recent algorithm enhancements receiving FDA clearance. New clinical trial results for its tubeless AID systems also indicate positive developments.

Despite the stock's recent underperformance compared to competitors like Zimmer Biomet Holdings, Inc., Wall Street analysts remain highly optimistic. With 25 analysts covering the stock, the consensus rating is a strong 'Buy.' The average price target suggests a potential upside of 63%, with some targets indicating an even higher potential return.

Analysts expect Insulet's diluted EPS to grow by 30% year-over-year to $6.46 for the current year, followed by a 24.2% increase to $8.02 in the next year. The stock has been trading below its 50-day and 200-day moving averages since December 2025, reflecting its recent downward trend.